萬馬科技(300698.SZ):2020年度預虧1000萬元–1200萬元
格隆匯 1 月 15日丨萬馬科技(300698.SZ)披露2020年度業績預吿,預計2020年度歸屬於上市公司股東的淨虧損1000萬元–1200萬元,上年同期盈利394.35萬元。業績變動原因如下:
1、受新冠肺炎疫情影響,公司經營情況受到較大沖擊,特別是對公司業績貢獻較大的數據中心板塊因業務公司在疫情中心武漢,上半年幾乎未正常開展業務。通信業務板塊,因行業週期致使收入下降因素仍然存在,市場份額和毛利情況都受到較大影響。而公司醫療板塊尚處於投入培育階段,利潤貢獻尚少。因此報吿期公司歸屬於上市公司股東的淨利潤同比大幅下降;
2、預計2020年公司非經常性損益對淨利潤的影響金額約為263萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.